Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients

Improving the chances of curing patients with cancer who have had surgery to remove metastatic sites of disease is a priority area for cancer research. Pexa-Vec (Pexastimogene Devacirepvec; JX-594, TG6006) is a principally immunotherapeutic oncolytic virus that has reached late-phase clinical trials...

Descripción completa

Detalles Bibliográficos
Autores principales: Samson, Adel, West, Emma J., Carmichael, Jonathan, Scott, Karen J., Turnbull, Samantha, Kuszlewicz, Bethany, Dave, Rajiv V., Peckham-Cooper, Adam, Tidswell, Emma, Kingston, Jennifer, Johnpulle, Michelle, da Silva, Barbara, Jennings, Victoria A., Bendjama, Kaidre, Stojkowitz, Nicolas, Lusky, Monika, Prasad, K.R., Toogood, Giles J., Auer, Rebecca, Bell, John, Twelves, Chris J., Harrington, Kevin J., Vile, Richard G., Pandha, Hardev, Errington-Mais, Fiona, Ralph, Christy, Newton, Darren J., Anthoney, Alan, Melcher, Alan A., Collinson, Fiona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381099/
https://www.ncbi.nlm.nih.gov/pubmed/35439304
http://dx.doi.org/10.1158/2326-6066.CIR-21-0171

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381099/
https://www.ncbi.nlm.nih.gov/pubmed/35439304
http://dx.doi.org/10.1158/2326-6066.CIR-21-0171

Ejemplares similares